Genetic Determinants of Lung Cancer Survival

This research project in the Epidemiology and Genetics of Lung Cancer Research Program at Mayo Clinic aims to ensure that the most effective treatment for lung cancer is offered to the right patient at the right time.

The Genetic Determinants of Lung Cancer Survival project focuses on:

  • Rigorously validating genomic markers through independent data sets from multiple institutions and providing answers about the relative impact of these markers on the short- and long-term outcomes of patients with lung cancer
  • Producing a web-based tool for researchers, clinicians and patients to help guide treatment selection and facilitate communication between researchers and providers

Working toward these goals, the research team is validating clinical models that accurately predict treatment outcomes and survival based on genomic markers in people with lung cancer and in their tumors. These models also can help predict therapy responses and survival endpoints, weighing in host and tumor markers to the established predictors.

In its work to effectively identify new and meaningful predictive biomarkers and potential therapeutic targets, the research team is exploring a variety of innovative approaches, including systems biology and deep nucleic acid sequencing.

Related publications

  • Sun Z, Wang L, Eckloff BW, Deng B, Wang Y, Wampfler JA, Jang J, Wieben ED, Jen J, You M, Yang P. Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Medical Genomics. 2014;7:32.
  • Deng B, Cassivi SD, de Andrade M, Nichols FC, Trastek VF, Wang Y, Wampfler JA, Stoddard SM, Wigle DA, Shen RK, Allen MS, Deschamps C, Yang P. Clinical outcomes and changes in lung function after segmentectomy versus lobectomy for lung cancer cases. The Journal of Thoracic and Cardiovascular Surgery. 2014;148(4):1186-1192.
  • Wu X, Wang L, Ye Y, Aakre JA, Pu X, Chang GC, Yang PC, Roth JA, Marks RS, Lippman SM, Chang JY, Lu C, Deschamps C, Su WC, Wang WC, Huang MS, Chang DW, Li Y, Pankratz VS, Minna JD, Hong WK, Hildebrandt MA, Hsiung CA, Yang P. Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. Cancer Research. 2013;73(13):4028-38.
  • Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C, Marks R, Fortner C, Stoddard S, Nichols F, Molina J, Aubry MC, Tang H, Yi ES. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. Journal of Thoracic Oncology. 2012;7(1):90-7.
  • Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. The Journal of the National Cancer Institute. 2011;103(10):817-25.
  • Sun Z, Chen J, Aakre J, Marks RS, Garces YY, Jiang R, Idowu O, Cunningham JM, Liu Y, Pankratz VS, Yang P. Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. Annals of Oncology. 2010;21(10):2011-6.
  • Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, Marks RS, Liu Y, Yang P. Prognostic factors for limited-stage small cell lung cancer: a study of 284 patients. Lung Cancer. 2010;67(2):221-6.
  • Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. Journal of Thoracic Oncology. 2009;4(4):479-85.